soul trial oral semaglutide cardiovascular outcomes 2025 and in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the Randomized Oral Semaglutide's Impact on Cardiovascular

The LEADER, SUSTAIN, SELECT, and FLOW trials established cardiovascular and renal outcomes

We reviewed Sikiric 1993-2026 (Zagreb, over 150 BPC-157 papers), the AJSM 2026 systematic review (35 preclinical studies), the 2026 pilot PK study in two healthy subjects, and the February 2026 STAT review

GHRH-based peptides take a lighter touch

Insulin directly affects the brain in several ways (all good): to start, insulin crosses the blood brain barrier and lands on specific insulin receptors in the brain

Walking is excellent for cardiovascular health, mental wellbeing, and calorie balance and it is strongly encouraged for people on GLP-1 drugs

Compounded Bioidentical Menopausal Hormone Therapy